Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer

  • Park, Jong-Lyul (Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Kim, Seon-Kyu (Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Kim, Jeong-Hwan (Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Yun, Seok Joong (Department of Urology, Chungbuk National University College of Medicine) ;
  • Kim, Wun-Jae (Department of Urology, Chungbuk National University College of Medicine) ;
  • Kim, Won Tae (Department of Urology, Chungbuk National University College of Medicine) ;
  • Jeong, Pildu (Department of Urology, Chungbuk National University College of Medicine) ;
  • Kang, Ho Won (Department of Urology, Chungbuk National University Hospital) ;
  • Kim, Seon-Young (Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology)
  • Received : 2018.05.08
  • Accepted : 2018.06.15
  • Published : 2018.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Because castration-resistant prostate cancer (CRPC) does not respond to androgen deprivation therapy and has a very poor prognosis, it is critical to identify a prognostic indicator for predicting high-risk patients who will develop CRPC. Here, we report a dataset of whole genomes from four pairs of primary prostate cancer (PC) and CRPC samples. The analysis of the paired PC and CRPC samples in the whole-genome data showed that the average number of somatic mutations per patients was 7,927 in CRPC tissues compared with primary PC tissues (range, 1,691 to 21,705). Our whole-genome sequencing data of primary PC and CRPC may be useful for understanding the genomic changes and molecular mechanisms that occur during the progression from PC to CRPC.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30. https://doi.org/10.3322/caac.21387
  2. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet 1995;346:265-269. https://doi.org/10.1016/S0140-6736(95)92163-X
  3. Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 2016;15: 699-718. https://doi.org/10.1038/nrd.2016.120
  4. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014;15:e404-e414. https://doi.org/10.1016/S1470-2045(14)70018-X
  5. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22. https://doi.org/10.1016/j.ccr.2010.05.026
  6. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-1228. https://doi.org/10.1016/j.cell.2015.05.001
  7. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An in- tegrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443-454. https://doi.org/10.1016/j.ccr.2010.03.018
  8. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castra- tion-resistant prostate cancer. Nature 2012;487:239-243. https://doi.org/10.1038/nature11125
  9. Park ES, Kim SJ, Kim SW, Yoon SL, Leem SH, Kim SB, et al. Cross-species hybridization of microarrays for studying tu- mor transcriptome of brain metastasis. Proc Natl Acad Sci U S A 2011;108:17456-17461. https://doi.org/10.1073/pnas.1114210108
  10. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-1760. https://doi.org/10.1093/bioinformatics/btp324
  11. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-1303. https://doi.org/10.1101/gr.107524.110
  12. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012;28:1811-1817. https://doi.org/10.1093/bioinformatics/bts271
  13. Li M, Stoneking M. A new approach for detecting low-level mutations in next-generation sequence data. Genome Biol 2012;13:R34. https://doi.org/10.1186/gb-2012-13-5-r34
  14. Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, et al. A comprehensive assessment of somatic muta- tion detection in cancer using whole-genome sequencing. Nat Commun 2015;6:10001. https://doi.org/10.1038/ncomms10001
  15. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013; 45:977-983. https://doi.org/10.1038/ng.2701
  16. Rubin MA, Demichelis F. The genomics of prostate cancer: a historic perspective. Cold Spring Harb Perspect Med 2018 Apr 30 [Epub]. https://doi.org/10.1101/cshperspect.a034942.
  17. Hovelson DH, Tomlins SA. The role of next-generation sequencing in castration-resistant prostate cancer treatment. Cancer J 2016;22:357-361. https://doi.org/10.1097/PPO.0000000000000217